These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 30798282)

  • 81. The effect of diabetes on the diagnostic and prognostic performance of mid-region pro-atrial natriuretic peptide and mid-region pro-adrenomedullin in patients with acute dyspnea.
    Wu AH; Tabas J; Stein J; Potocki M; Mueller C; McCord J; Richards M; Hartmann O; Nowak R; Peacock WF; Ponikowski P; Moeckel M; Hogan C; Filippatos GS; Di Somma S; Anand I; Ng L; Neath SX; Christenson R; Morgenthaler NG; Anker SD; Maisel AS
    Biomarkers; 2012 Sep; 17(6):490-7. PubMed ID: 22616939
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Postoperative pro-adrenomedullin levels predict mortality in thoracic surgery patients: comparison with Acute Physiology and Chronic Health Evaluation IV Score*.
    Schoe A; Schippers EF; Struck J; Ebmeyer S; Klautz RJ; de Jonge E; van Dissel JT
    Crit Care Med; 2015 Feb; 43(2):373-81. PubMed ID: 25599464
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Multidimensional Prognostic Index and pro-adrenomedullin plasma levels as mortality risk predictors in older patients hospitalized with community-acquired pneumonia: a prospective study.
    Pilotto A; Dini S; Veronese N; Daragjati J; Miolo M; Mion MM; Fontana A; Lo Storto M; Zaninotto M; Bragato G; Cella A; Carraro P; Addante F; Copetti M; Plebani M
    Panminerva Med; 2018 Sep; 60(3):80-85. PubMed ID: 29546738
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Mid-regional pro-adrenomedullin improves disposition strategies for patients with acute dyspnoea: results from the BACH trial.
    Möckel M; Searle J; Hartmann O; Anker SD; Peacock WF; Wu AH; Maisel A; ; Slagman A; Vollert JO; Papassotiriou J; Anand I; Christenson R; Daniels LB; Filippatos GS; Hogan C; Morgenthaler N; Mueller C; Neath SX; Ng L; Nowak R; Richards M; Di Somma S; Ponikowski P
    Emerg Med J; 2013 Aug; 30(8):633-7. PubMed ID: 22962091
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Stable State Proadrenomedullin Level in COPD Patients: A Validation Study.
    Zuur-Telgen M; VanderValk P; van der Palen J; Kerstjens HA; Brusse-Keizer M
    COPD; 2017 Apr; 14(2):219-227. PubMed ID: 27880050
    [TBL] [Abstract][Full Text] [Related]  

  • 86. The diagnostic accuracy of mid-regional pro-adrenomedullin for sepsis: a systematic review and meta-analysis.
    Li P; Wang C; Pang S
    Minerva Anestesiol; 2021 Oct; 87(10):1117-1127. PubMed ID: 34134460
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Diagnostic performance of mid-regional pro-adrenomedullin as an analyte for the exclusion of left ventricular dysfunction.
    Elmas E; Lang S; Dempfle CE; Kälsch T; Papassotiriou J; Morgenthaler NG; Borggrefe M; Brueckmann M
    Int J Cardiol; 2008 Aug; 128(1):107-11. PubMed ID: 17698224
    [TBL] [Abstract][Full Text] [Related]  

  • 88. The TRIAGE-ProADM Score for an Early Risk Stratification of Medical Patients in the Emergency Department - Development Based on a Multi-National, Prospective, Observational Study.
    Kutz A; Hausfater P; Amin D; Amin A; Canavaggio P; Sauvin G; Bernard M; Conca A; Haubitz S; Struja T; Huber A; Mueller B; Schuetz P;
    PLoS One; 2016; 11(12):e0168076. PubMed ID: 28005916
    [TBL] [Abstract][Full Text] [Related]  

  • 89. The use of mid-regional proadrenomedullin to identify disease severity and treatment response to sepsis - a secondary analysis of a large randomised controlled trial.
    Elke G; Bloos F; Wilson DC; Brunkhorst FM; Briegel J; Reinhart K; Loeffler M; Kluge S; Nierhaus A; Jaschinski U; Moerer O; Weyland A; Meybohm P;
    Crit Care; 2018 Mar; 22(1):79. PubMed ID: 29562917
    [TBL] [Abstract][Full Text] [Related]  

  • 90. New role of biomarkers: mid-regional pro-adrenomedullin, the biomarker of organ failure.
    Valenzuela-Sánchez F; Valenzuela-Méndez B; Rodríguez-Gutiérrez JF; Estella-García Á; González-García MÁ
    Ann Transl Med; 2016 Sep; 4(17):329. PubMed ID: 27713887
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Clinical Utility of Midregional Proadrenomedullin in Patients with COVID-19.
    Lo Sasso B; Gambino CM; Scichilone N; Giglio RV; Bivona G; Scazzone C; Muratore R; Milano S; Barbagallo M; Agnello L; Ciaccio M
    Lab Med; 2021 Sep; 52(5):493-498. PubMed ID: 33928380
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Biomarkers from distinct biological pathways improve early risk stratification in medical emergency patients: the multinational, prospective, observational TRIAGE study.
    Schuetz P; Hausfater P; Amin D; Amin A; Haubitz S; Faessler L; Kutz A; Conca A; Reutlinger B; Canavaggio P; Sauvin G; Bernard M; Huber A; Mueller B;
    Crit Care; 2015 Oct; 19():377. PubMed ID: 26511878
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Performance of pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia.
    España PP; Capelastegui A; Mar C; Bilbao A; Quintana JM; Diez R; Esteban C; Bereciartua E; Unanue U; Uranga A
    J Infect; 2015 May; 70(5):457-66. PubMed ID: 25499199
    [TBL] [Abstract][Full Text] [Related]  

  • 94. MR-proADM: A New Biomarker for Early Diagnosis of Sepsis in Burned Patients.
    Gille J; Ostermann H; Dragu A; Sablotzki A
    J Burn Care Res; 2017; 38(5):290-298. PubMed ID: 28221298
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Adrenomedullin Is Associated With Surgical Trauma and Impaired Renal Function in Vascular Surgery Patients.
    Gillmann HJ; Meinders A; Larmann J; Sahlmann B; Schrimpf C; Aper T; Lichtinghagen R; Teebken OE; Theilmeier G
    J Intensive Care Med; 2019 Jan; 34(1):67-76. PubMed ID: 28110613
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Midregional proadrenomedullin (MR-proADM) in the risk stratification of patients with acute pulmonary embolism.
    Pedowska-Włoszek J; Kostrubiec M; Kurnicka K; Ciurzynski M; Palczewski P; Pruszczyk P
    Thromb Res; 2013 Nov; 132(5):506-10. PubMed ID: 24060192
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Diagnostic performance and reference values of novel biomarkers of paediatric heart failure.
    Hauser JA; Demyanets S; Rusai K; Goritschan C; Weber M; Panesar D; Rindler L; Taylor AM; Marculescu R; Burch M; Wojta J; Michel-Behnke I
    Heart; 2016 Oct; 102(20):1633-9. PubMed ID: 27220692
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes.
    Zabarovskaja S; Hage C; Linde C; Daubert JC; Donal E; Gabrielsen A; Mellbin L; Lund LH
    Int J Cardiol; 2015; 189():6-11. PubMed ID: 25885866
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study.
    Khan SQ; O'Brien RJ; Struck J; Quinn P; Morgenthaler N; Squire I; Davies J; Bergmann A; Ng LL
    J Am Coll Cardiol; 2007 Apr; 49(14):1525-32. PubMed ID: 17418290
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Usefulness of several biomarkers in the management of septic patients: C-reactive protein, procalcitonin, presepsin and mid-regional pro-adrenomedullin.
    Enguix-Armada A; Escobar-Conesa R; García-De La Torre A; De La Torre-Prados MV
    Clin Chem Lab Med; 2016 Jan; 54(1):163-8. PubMed ID: 26083268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.